Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal remifentanil vs intranasal dexmedetomidine for hemodynamic response to tracheal intubation
IRCT20130311012782N60Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of remifentanil and dexmedetomidine (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in heart rate after tracheal intubation and Change in blood pressure after tracheal intubation. Started Apr 2024; status: completed.
02
Drugs
remifentanildexmedetomidine
Beyond the preview
Go deeper on IRCT20130311012782N60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130311012782N60.